Evidence map›Paper›PMID 22913465›Full record

ArticleCanadian journal of physiology and pharmacology2012

d-Propranolol protects against oxidative stress and progressive cardiac dysfunction in iron overloaded rats.

Jay H Kramer, Christopher F Spurney, Micaela Iantorno, Constantine Tziros, Joanna J Chmielinska, I Tong Mak, William B Weglicki

Abstract read
In one paragraph

Article in Canadian journal of physiology and pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Chia seeds and coenzyme QScientific reports · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jay H KramerBiochemistry & Molecular Biology, Division of Experimental Medicine, The George Washington University Medical Center, Washington, DC 20037, USA. phyjhk@gwu.edu
Christopher F Spurney
Micaela Iantorno
Constantine Tziros
Joanna J Chmielinska
I Tong Mak
William B Weglicki
George Washington University · USChildren's National · USWashington University Medical Center · US

Funding

OXIDATIVE STRESS AND ANTIOXIDANTS IN IRON OVERLOADR01HL066226 · NHLBI · GEORGE WASHINGTON UNIVERSITY · PI WEGLICKI, WILLIAM BERNARD · 2000 to 2010
$3.1M
NHLBI NIH HHS R01 HL066226NHLBI NIH HHS R01-HL66226
6 · The paper itself

Abstract

d-Propranolol (d-Pro: 2-8 mg·(kg body mass)(-1)·day(-1)) protected against cardiac dysfunction and oxidative stress during 3-5 weeks of iron overload (2 mg Fe-dextran·(g body mass)(-1)·week(-1)) in Sprague-Dawley rats. At 3 weeks, hearts were perfused in working mode to obtain baseline function; red blood cell glutathione, plasma 8-isoprostane, neutrophil basal superoxide production, lysosomal-derived plasma N-acetyl-β-galactosaminidase (NAGA) activity, ventricular iron content, and cardiac iron deposition were assessed. Hearts from the Fe-treated group of rats exhibited lower cardiac work (26%) and output (CO, 24%); end-diastolic pressure rose 1.8-fold. Further, glutathione levels increased 2-fold, isoprostane levels increased 2.5-fold, neutrophil superoxide increased 3-fold, NAGA increased 4-fold, ventricular Fe increased 4.9-fold; and substantial atrial and ventricular Fe-deposition occurred. d-Pro (8 mg) restored heart function to the control levels, protected against oxidative stress, and decreased cardiac Fe levels. After 5 weeks of Fe treatment, echocardiography revealed that the following were depressed: percent fractional shortening (%FS, 31% lower); left ventricular (LV) ejection fraction (LVEF, 17%), CO (25%); and aortic pressure maximum (P(max), 24%). Mitral valve E/A declined by 18%, indicating diastolic dysfunction. Cardiac CD11b+ infiltrates were elevated. Low d-Pro (2 mg) provided modest protection, whereas 4-8 mg greatly improved LVEF (54%-75%), %FS (51%-81%), CO (43%-78%), P(max) (56%-100%), and E/A >100%; 8 mg decreased cardiac inflammation. Since d-Pro is an antioxidant and reduces cardiac Fe uptake as well as inflammation, these properties may preserve cardiac function during Fe overload.

Indexed as

AcetylglucosaminidaseAdrenergic beta-AntagonistsAnimalsCardiac OutputDisease ProgressionDose-Response Relationship, DrugEchocardiographyErythrocytesGlutathioneHeart DiseasesIron OverloadMaleMyocardiumNeutrophilsOxidative StressPerfusionAcetylglucosaminidaseAdrenergic beta-AntagonistsGlutathionePropranololSuperoxide Dismutase

Identifiers

PMID22913465
PMCPMC3715050
OpenAlexW1977102315

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.